The Monkeypox Vaccine And Treatment Market Size is valued at 85.86 Million in 2023 and is predicted to reach 212.34 Million by the year 2031 at an 12.39 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
Humans can contract monkeypox by coming into intimate contact with an animal or person with the disease and by contact with contaminated objects. A viral zoonotic illness called monkeypox primarily affects tropical rainforest regions. It frequently manifests clinically as a rash, fever, and swollen lymph nodes and can cause various health issues. The monkeypox vaccines employed in the smallpox eradication operation also offered protection from that disease. One of the more recent vaccinations created is licensed to prevent monkeypox. The market is expected to be driven by elements like the rising incidence of monkeypox infection worldwide and the rising demand for treatment and prevention strategies. In addition, a surge in product approvals and rising government efforts to fund research into monkeypox infection are anticipated to propel market expansion. As of September 8, 2022, 56,609 cases had been reported worldwide, with 18 fatalities, according to CDC data. Most cases have been reported in the United States and Europe.
Market participants are encouraged by the rising incidence rates in these places to create cutting-edge drugs to lessen the disease burden there. Additionally, it is projected that several government programs for the supply, distribution, and availability of vaccinations to prevent infection will promote market growth in the years to come. The EUA and ongoing regulatory approvals both help the market grow. The market is anticipated to be driven by increased R&D and the smallpox vaccine as an off-label product for vaccination against monkeypox.
The Monkeypox Vaccine And Treatment market is segmented on the product, route of administration and end-use. Based on product, the market is segmented into Vaccines (JYNNEOS/ Imvanex, Smallpox Vaccine, Others), Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others) and Vaccinia Immune Globulin (VIG). Based on gender, Monkeypox Vaccine And Treatment market is segmented into males, females and Others. Based on the route of administration, the Monkeypox Vaccine And Treatment market is segmented into Oral and Injectable. Based on end-use, the Monkeypox Vaccine And Treatment market is segmented into Hospitals, Specialty Clinics and Others.
The market's leading segment was drugs. Some of the main drivers of the expansion include an expanding patient population for monkeypox disease, an increase in the use of antiviral drugs, and high treatment costs for the symptomatic management of the illness. However, the vaccine segment is anticipated to grow significantly. Increased use of vaccines against monkeypox infection, greater public awareness of vaccination, and intensive R&D efforts to create novel medicines are all predicted to boost category expansion. Additionally, several government measures to increase vaccine accessibility are projected to support category growth.
Hospitals grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Growth is anticipated to be fueled by an increase in hospitalizations brought on by the monkeypox outbreak and a rise in the demand for therapeutic items used for symptomatic treatment in hospitals. Additionally, several initiatives launched by governmental organizations like the American Hospital Association and the Department of Health and Human Services to enhance the care and ongoing surveillance of patients with monkeypox infections are growing the hospital's patient base.
The North American Monkeypox Vaccine And Treatment market is expected to register the highest market share in revenue in the near future due to numerous key individuals and the numerous strategic efforts they have made. Additionally, it is anticipated that increased vaccination awareness and an increase in illness prevalence will encourage regional market growth. Furthermore, it is projected that solid government backing and increased R&D spending will create profitable growth prospects for the North American region. In addition, Asia Pacific is projected to grow rapidly in the global Monkeypox Vaccine And Treatment market. Monkeypox infections are arising, and research and development funds are being spent to establish preventative and therapeutic measures. As infection rates rise in countries around the Asia Pacific, including Australia, Singapore, and India, the market is expected to grow.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 85.86 Million |
| Revenue Forecast In 2031 | USD 212.34 Million |
| Growth Rate CAGR | CAGR of 12.39 % from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product, Gender, Route of Administration, End-Use |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Bavarian Noric; SIGA Technologies; Chimerix; EMERGENT; Gilead Sciences, Inc.Enthoven, Pulviver, Wulro Bv, and Venky’s(India) Limited |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Product-
By Gender-
By Route of Administration-
By End-Use
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.